Document:

<PAGE>

[CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.]

                                                                   Exhibit 10.11

                    FIRST AMENDMENT TO THE AGREEMENT ENTITLED
                  "ASSIGNMENT OF PATENT RIGHTS AND TECHNOLOGY"
                       ENTERED INTO AUGUST 1, 1991 BETWEEN
         THE UNIVERSITY OF TEXAS, ADAM HELLER, AND E. HELLER AND COMPANY
                                (THE "AMENDMENT")

        WHEREAS, under the August 1, 1991, agreement entitled "Assignment of
Patent Rights and Technology" (hereafter "Assignment"), and Exhibit A hereto,
the Board of Regents of the University of Texas System on behalf of The
University of Texas at Austin (hereafter collectively referred to as "Assignor")
assigned to E. Heller and Company ("Assignee") its right, title, and interest
in, to, and under the Patent Rights and the Technology (as such terms are
defined in the Assignment); and

        WHEREAS, under Paragraph 3.1 of the Assignment the parties agreed that
in return for its assignment of rights, Assignor would be compensated as noted
in the event Patent Rights, the Technology, and the Know-How are sold, licensed,
or otherwise disposed of for value to a third party or parties; and under
Paragraph 3.2 of the Assignment the parties also agreed that Assignor would be
compensated for a to-be-negotiated amount should Assignee elect to itself
manufacture, sell, or otherwise dispose of for value Licensed Products and
Licensed Processes (as such terms are defined in the Assignment) and which are
derived from the Patent Rights, the Technology, and the Know-How; and

        WHEREAS, since the effective date of the Assignment, Assignee has
invested approximately *** in research and development of biosensors
within the scope of the Technology, Patent Rights, and Know-How, and estimates
that an additional investment of approximately *** will be necessary to
complete product development and enter into clinical trials, and Assignee, on
behalf of itself and its Affiliates (as defined below), has now elected to
manufacture, sell, or otherwise dispose of for value, including sublicensing,
the Patent Rights, Technology, Know-How, Licensed Products, and Licensed
Processes; and

        WHEREAS, Assignor and Assignee now desire to amend Paragraphs 3.1 and
3.2 and certain other paragraphs of the Assignment and specifically set out
herein the mutually agreed compensation due Assignor for Assignee's disposition
for value of the Patent Rights, the Technology, the Know-How, Licensed Products
and Licensed Processes.

        NOW, THEREFORE, in consideration of the covenants and agreements
herein contained the parties agree as follows:

1.      All capitalized terms not defined in this Amendment shall have the
        meaning given to them in the Assignment.

2.      Section 1.2 is amended to read in its entirety as follows:

        1.2  Patent Rights. The term "Patent Rights" as used herein shall mean
             -------------
        Assignor's rights in all inventions and intellectual property disclosed
        in the patent applications patents and other invention disclosures
        listed on Exhibit B and Exhibit C hereto, including all U.S. and

*** Confidential treatment requested
<PAGE>

         foreign patent applications including provisional applications, and all
         divisions, continuations, continuations in-part, and substitutions
         thereof; all foreign patent applications corresponding to the preceding
         applications; and all U.S. and foreign patents issuing on any of the
         preceding applications, including extensions, reissues, and re-
         examinations.

3.       Section 1.3 is amended to read in its entirety as follows:

         1.3   Know-How. The term "Know How" as used herein shall mean
               --------
         Assignor's rights in all ideas, inventions, data, trade secrets,
         instructions, processes, formulas, chemical, pharmacological,
         toxicological, pharmaceutical, physical and analytical, manufacturing
         (including but not limited to processes, yields, reagants and
         conditions relating to compound manufacture) data and information,
         owned or controlled by Assignor existing as of the last signature date
         of this Assignment which are generally not known, and which are
         necessary or useful for the manufacture of Licensed Products. Excluded
         from Know-How are any inventions included with Patent Rights.

4.       Section 1.4 is amended to read in its entirety as follows:

         1.4   Licensed Products. The term "Licensed Products" as used herein
               -----------------
         shall mean any product which (i) is covered by a Valid Claim in the
         country such product is made or sold, or (ii) incorporates in material
         part or is made using the Technology, Know-How, Licensed Processes or
         Other Intellectual Property. For the avoidance of doubt, subject to the
         foregoing, a Licensed Product unit shall mean any instrument or
         associated disposable.

5.       Article 1 is amended to add new Section 1.7 as follows:

         1.7   Affiliate. The term "Affiliate" as used herein shall mean any
               ---------
         corporation or other entity which is directly or indirectly
         controlling, controlled by or under the common control with a party
         hereto. For the purposes of this definition, "control" shall mean the
         direct or indirect ownership of at least fifty percent (50%) of the
         outstanding shares or other voting rights of the subject entity to
         elect directors, or if not meeting the preceding, any entity owned or
         controlled by or owning or controlling at the maximum control or
         ownership right permitted in the country where such entity exists.

6.       Article 1 is amended to add new Section 1.8 as follows:

         1.8   Net Sales. The term "Net Sales" as used herein shall mean the
               ---------
         gross revenues received by Assignee, its Affiliates or sublicensees
         from sales of Licensed Products, less (i) normal and customary rebates,
         and cash and trade discounts, actually taken, (ii) sales, value-added,
         use and/or other excise taxes or duties actually paid, (iii) outbound
         transportation charges prepaid or allowed, (iv) import and/or export
         duties actually paid, and (v) amounts allowed or credited due to
         returns.

7.       Article 1 is amended to add new Section 1.9 as follows:

         1.9   Valid Claim. The term "Valid Claim" as used herein shall mean (i)
               -----------
         a claim of an issued and unexpired patent included within the Patent
         Rights which has not been disclaimed

                                      -2-
<PAGE>

         or admitted to be invalid or unenforceable through reissue or
         otherwise, or (ii) a claim of a pending application within the Patent
         Rights provided that not more than five (5) years have elapsed from the
         date the claim takes priority for filing purposes.

8.       Article 1 is amended to add new Section 1.10 as follows:

         1.10  Dominating Patent. The term "Dominating Patent" as used herein
               -----------------
         shall mean an unexpired patent which is owned by a third party covering
         Licensed Products made and sold by Assignee or its sublicensees under
         circumstances such that Assignee or its sublicensee has no commercially
         reasonable alternative but to obtain a license under such patent in
         order to make, use or commercialize a Licensed Product.

9.       Article 1 is amended to add new Section 1.11 as follows:

         1.11  Other Intellectual Property. The term "Other Intellectual
               ---------------------------
         Property" as used herein shall mean Board's rights in any biosensor
         related inventions (whether or not patentable), improvements,
         discoveries, developments, original works of authorship, software,
         trade secrets, Know-How made, conceived, reduced to practice or
         otherwise developed, by an employee of Assignor pursuant to either (i)
         a consulting agreement entered into by such employee and EHC or its
         sublicensee; or (ii) any similar agreement between an employee of the
         University of Texas at Austin and Assignee, and all intellectual
         property rights therein and thereto, shall be subject to the Assignment
         in Section 2.1 below.

10.      Section 2.1 is amended to read in its entirety as follows:

         2.1   Assignment by Assignor. Assignor hereby transfers, assigns,
               ----------------------
         sells, and conveys to Assignee, its successors and assigns, the entire
         right, title and interest throughout the world in and to the Patent
         Rights, Technology, Know-How, and Other Intellectual Property subject
         only to: (a) any rights of the United States Government which may exist
         now or in the future due to a research funding agreement to which the
         United States Government may be a party; and (b) the terms and
         conditions of this Agreement.

11.      Article 3 is amended to read in its entirety as follows:

         3.1   Royalties. In consideration for the Assignment herein, Assignee
               ---------
         shall pay to Assignor the greater of (i) an annual minimum royalty of
         twenty thousand dollars or (ii) royalties on Net Sales of Licensed
         Products sold by Assignee, an Affiliate or its sublicensees which are
         within the scope of a Valid Claim as follows:

                                      Numbers of Licensed
         Royalty Rate                 Products Sold Worldwide During the Term
         ------------                 ---------------------------------------

         ***  of Net Sales            1-100,000

         ***  of Net Sales            100,001-200,000

         ***  of Net Sales            200,001-and above

*** Confidential treatment requested

                                      -3-
<PAGE>

         Any minimum annual royalty payable hereunder shall be fully creditable
         against any running royalty payable to Assignor during such year.

         3.2   Sublicense Payment. In addition to the royalties subject to
               ------------------
         Section 3.1 above, Assignee shall pay to Assignor *** received by
         Assignee and its Affiliates from licensees and sublicensees of the
         Patent Rights, Know-How, Technology or Other Intellectual Property.
         Notwithstanding the foregoing, it is understood and agreed that
         Assignor shall not be entitled to any portion of amounts received from
         licensees or sublicensees for equity in Assignee less than *** of
         fair market value, debt financing, research and development funding,
         the license or sublicense of any intellectual property other than the
         Patent Rights, Know-how, Technology or Other Intellectual Property, or
         reimbursement for patent or other expenses, and to be determined in a
         manner consistent with generally accepted accounting principles (GAAP).

         3.3   Royalties on Combination Products. In the event that a Licensed
               ---------------------------------
         Product is sold by Assignee, an Affiliate or its sublicensee in
         combination as a single product with another product whose sale and use
         are not within the scope of a Valid Claim in the country for which the
         combination product is sold, Net Sales from such sales for purposes of
         calculating the amounts due under Section 3.1 above shall be calculated
         by multiplying the Net Sales of that combination by the fraction A/(A +
         B), where A is the gross selling price of the Licensed Product sold
         separately and B is the gross selling price of the other product sold
         separately. In the event that no such separate sales are made by
         Assignee, an Affiliate or its sublicensee, Net Sales for royalty
         determination shall be as reasonably allocated by Assignee, an
         Affiliate or its sublicensee between such Licensed Product and such
         other product, based upon their relative importance and proprietary
         protection. Notwithstanding the above, in no event shall Assignor
         receive a royalty of less *** of the running royalty amount per unit of
         Licensed Product due under Section 3.1 above.

         3.4   Third Party Royalty Offset. In the event Assignee, an Affiliate
               --------------------------
         or its sublicensee enters into a license agreement with any third party
         with respect to a Dominating Patent or to settle a claim of
         infringement or misappropriation of any intellectual property of a
         third party relating to the practice or use of the Technology and or
         Know-How, Assignee, an Affiliate or its sublicensee may offset any
         payments made in accordance with such license agreements against any
         amounts of running royalties owned by Assignee pursuant to Article 3
         herein up to a maximum of *** of the amount otherwise due to such third
         party; provided, however that in no event will the running royalties
         due to Assignor be lower than the following:

         Royalty Rate                Number of Licensed Products Sold Worldwide
         ------------                ------------------------------------------
                                     During the Term
                                     ---------------

         ***  of Net Sales           1-100,000

         ***  of Net Sales           100,001-200,000

         ***  of Net Sales           200,001 - and above

                                      -4-

***  Confidential treatment requested
<PAGE>

         In addition, in such event, the amounts due to Assignor under Section
         3.2 above shall be reduced by an amount equal to *** the amount paid
         to such third party.

         3.5   One Royalty. No more than one royalty payment shall be due with
               -----------
         respect to a sale of a particular Licensed Product. No multiple
         royalties shall be payable because any Licensed Product, or its
         manufacture, use or sale is covered by more than one Valid Claim. No
         royalty shall be payable under this Article 3 with respect to Licensed
         Products distributed for use in research and/or development, in
         clinical trials or as promotional samples.

         3.6   Royalty Term. Royalties due under this Article 3 shall be payable
               ------------
         on a country-by-country and Licensed Product-by-Licensed Product basis
         until the expiration of the last-to-expire issued Valid Claim covering
         such Licensed Product in such country, or if no such Valid Claim issued
         in a country, until the fifth anniversary of the first commercial sale
         of a Licensed Product in such country.

         3.7   In the event Assignee engages in litigation and/or settlement
         negotiations to advance a claim it makes that a third party is
         infringing on Licensed Products and/or Licensed Processes, ***
         on any litigation or settlement recovery by Assignee will be paid to
         Assignor; provided, however, that Assignee shall be entitled to first
         deduct reasonable and documented attorney's and other professional
         fees, expert fees, court costs, and other reasonable expenses incurred
         by Assignee in such litigation and/or settlement activities.

12.      Section 4.2 is amended to read in its entirety as follows:

         4.2   Payments and Reports. The first annual minimum royalty payment of
               --------------------
         twenty thousand dollars ($20,000) shall be due and payable to Assignor
         within 30 days of the date of the last signature on this Amendment.
         Thereafter, minimum annual royalty payments, when due, shall be due and
         payable within thirty (30) days after the end of the applicable year.
         All running royalties payable hereunder by Assignee shall be due within
         thirty (30) days following the end of each respective semi-annual
         reporting period, which ending dates shall be June 30 and December 31
         for each successive year. Each report will accurately identify income
         and expenses in sufficient form and detail so as to enable Assignor to
         determine the royalties due for such semi-annual period, and shall be
         mailed to the following: Office of the Executive Vice President and
         Provost, The University of Texas at Austin, Main Building 201, Austin,
         Texas 78712-1111, ATTN: Patricia C. Ohlendorf, with a copy to the
         Office of Technology Licensing and Intellectual Property at the address
         listed in 16.3 herein. Checks shall be made payable to The University
         of Texas at Austin. Except as expressly provided herein, all amounts
         payable hereunder shall be payable in United States dollars without
         deductions for taxes, assessments, fees, or charges of any kind.

13.      Article 15 is amended to read in its entirety as follows:

         15.1  Assignment. Neither party may assign this Assignment without the
               ----------
         prior consent of the other, which consent shall not be unreasonably
         withheld; provided, however, Assignee may assign this Assignment in
         connection with a transfer of all or substantially all of its

***  Confidential treatment requested

                                      -5-

<PAGE>

     assets relating to this Assignment, whether by sale, merger, operation of
     law or otherwise. This Assignment shall be binding upon and inure to the
     benefit of the parties and their successors and assigns.

14.  New Article 16 is added as follows:

     MISCELLANEOUS
     -------------

     16.1  Affiliate Rights/Obligations. Assignee shall have the right to extend
           ----------------------------
     the provisions of the Assignment regarding the right to manufacture, sell,
     or otherwise dispose of for value, including licensing and sublicensing,
     the Patent Rights, Technology, Know-How, Other Intellectual Property,
     Licensed Products, and Licensed Processes, to any Affiliate, provided such
     Affiliate consents to be bound by the Assignment to the same extent as
     Assignee. Further, Assignee shall have the right to extend the provisions
     of this Amendment in their entirety to any Affiliate, provided such
     Affiliate consents to be bound by the applicable provisions of this
     Amendment to the same extent as Assignee.

     16.2  Entire Agreement. The Assignment and this Amendment constitute the
           ----------------
     entire and only agreement between the parties with respect to the Patent
     Rights, Technology, Know-How, Other Intellectual Property, Licensed
     Products, and Licensed Processes, and all other prior negotiations,
     representations, agreements, and understandings are superseded hereby. No
     agreement altering or supplementing the terms of the Assignment may be made
     except by means of a written document signed by a duly authorized
     representative of each party.

     16.3. Notices. Any notices under this Assignment or shall be given by
           -------
     prepaid, first class, certified mail, return receipt requested, addressed
     as follows (or such other address as may be given from time to time under
     the terms of this provision):

<TABLE>
     <S>                                            <C>
     in the case of Assignor -                       with a copy to -
     BOARD OF REGENTS                                OFFICE OF THE EXECUTIVE
     The University of Texas System                  VICE PRESIDENT & PROVOST
     201 West 7th Street                             The University of Texas at Austin
     Austin, Texas  78701                            Austin, Texas 78712-1111
     ATTN: System Intellectual Property Office       ATTN:  Patricia C. Ohlendorf

                                                     with a copy to -
                                                     OFFICE OF TECHNOLOGY LICENSING AND
                                                     INTELLECTUAL PROPERTY
                                                     The University of Texas at Austin
                                                     MCC Building
                                                     Suite 1.9A
                                                     3925 West Braker Lane
                                                     Austin, Texas  78759
                                                     ATTN:  Director
</TABLE>

                                      -6-
<PAGE>

         or in the case of Assignee -

         E. HELLER AND COMPANY
         1311 Harbor Bay Parkway, Suite 1000
         Alameda, California  94502
         ATTN:  Ephraim Heller

         16.4  LIMITATION OF LIABILITY. SUBJECT TO ARTICLE XIV OF THE
               -----------------------
         ASSIGNMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
         CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS
         ASSIGNMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY

         16.5  Right to Independently Develop. Nothing in this Assignment will
               ------------------------------
         impair Assignee's right to independently acquire, license, develop for
         itself, or have others develop for it, technology or intellectual
         property performing the same or similar functions as the Know-How or
         the Patent Rights, or the Other Intellectual Property, or to market and
         distribute licensed products based on such other intellectual property
         and technology.

         16.6  Further Assurances. At any time or from time to time on and after
               ------------------
         the date of this Assignment, Assignor shall at the request and sole
         expense of Assignee (i) deliver to Assignee such records, data or other
         documents consistent with the provisions of this Assignment, (ii)
         execute, and deliver or cause to be delivered, all such consents,
         documents or further instruments of transfer or license, and (iii) take
         or cause to be taken all such actions, as Assignee may reasonably deem
         necessary or desirable in order for Assignee to obtain the full
         benefits of the Assignment and Amendment and the transactions
         contemplated hereby.

         16.7  Severability. In the event that any provisions of this Assignment
               ------------
         are determined to be invalid or unenforceable by a court of competent
         jurisdiction, the remainder of the Assignment shall remain in full
         force and effect without said provision. The parties shall in good
         faith negotiate a substitute clause for any provision declared invalid
         or unenforceable which shall most nearly approximate the intent of the
         parties in entering this Assignment.

         16.8  Modification; Waiver. This Assignment may not be altered, amended
               --------------------
         or modified in any way except by a writing signed by both parties. The
         failure of a party to enforce any provision of the Assignment shall not
         be construed to be a waiver of the right of such party to thereafter
         enforce that provision or any other provision or right.

15.      Except as specifically modified or amended hereby, the Assignment shall
         remain in full force and effect and, as so modified or amended, is
         hereby ratified, confirmed and approved. No provision of this Amendment
         may be modified or amended except expressly in a writing signed by both
         parties nor shall any terms be waived except expressly in a writing
         signed by the party charged therewith. This Amendment shall be governed
         in accordance with the laws of the State of Texas, without regard to
         principles of conflicts of laws.

                                      -7-
<PAGE>

         IN WITNESS WHEREOF, this Amendment effective as of March 19, 1998, is
hereby executed by the duly authorized representatives of the parties on the
date indicated below in duplicate, each of which shall be deemed an original and
together shall form one and the same instrument.

BOARD OF REGENTS OF THE
UNIVERSITY OF TEXAS SYSTEM                       E. HELLER AND COMPANY

/s/ Ray Farabee                                  /s/ Ephraim Heller
---------------------------------------          -------------------------------
Ray Farabee                                      Ephraim Heller
Vice Chancellor and General Counsel              President
Date:   4/7/98                                   Date:   3/19/98
     ----------------------------------               --------------------------

APPROVED AS TO CONTENT                           ADAM HELLER

/s/ Patricia C. Ohlendorf                        /s/ Adam Heller
---------------------------------------          -------------------------------
Patricia C. Ohlendorf                            Adam Heller
Counsel to the President                         Date:   3/19/98
                                                      --------------------------
Vice Provost
Date:   3/27/98
     ----------------------------------

APPROVED AS TO FORM

/s/ Georgia Harper
---------------------------------------

Name: Georgia Harper
     ----------------------------------
Office of General Counsel
Date: 4/7/98
     ----------------------------------

                                      -8-
<PAGE>

                                   EXHIBIT A

                              [See Exhibit 10.10]
<PAGE>

                                   EXHIBIT B

                                 (See attached)
<PAGE>

COLLEGE OF ENGINEERING

THE UNIVERSITY OF TEXAS AT AUSTIN

Department of Chemical Engineering, Austin, Texas 78712-1062

Adam Heller                                                     January 6, 1997
Ernest Cockrell, Sr. Chair
Telephone:      (512) 471-8874
FAX:            (512) 471-8799
e-mail:         heller@che.utexas.edu

To:             Dr. Paulette Braeutigam, Technology
                    Licensing Coordinator

From:           Adam Heller

Dear Paulette:

This letter follows your discussion with Ephraim wherein you agreed to cover in
the current agreement between The University of Texas at Austin and E. Heller &
Company all presently existing intellectual property relating to biosensors that
originated in my group. These include the following:

US Patents Issued:
-----------------

The already issued patents are:

US 5,543,326 - Biosensor including chemically modified enzymes.

US 5,356,786 - Interferant eliminating biosensor

US 5,320,725 - Electrode and Method for the detection of hydrogen peroxide.

US 5,264,105 - Enzyme electrodes.

US 5,264,104 - Enzyme electrodes.

US 5,262,305 - Interferant eliminating biosensor.

US 5,262,035 - Enzyme electrodes.

<PAGE>

US Patents Currently Prosecuted:
-------------------------------

(1)    ***

                                      -2-

*** Confidential treatment requested
<PAGE>

***

*** Confidential treatment requested

                                      -3-
<PAGE>

***

*** Confidential treatment requested

                                      -4-
<PAGE>

***

*** Confidential treatment requested

                                      -5-
<PAGE>

***

*** Confidential treatment requested
                                      -6-

<PAGE>

***

*** Confidential treatment requested

                                      -7-

<PAGE>

***

*** Confidential treatment requested

                                      -8-

<PAGE>

***

With my regards and best wishes for 1997.

Adam Heller

AH:n

*** Confidential treatment requested

                                      -9-<PAGE>

[CONFIDENTIAL TREATMENT REQUESTED, CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.]

                                                                   Exhibit 10.14

                      INTERNATIONAL DISTRIBUTOR AGREEMENT

     This INTERNATIONAL DISTRIBUTOR AGREEMENT (the "Agreement") is entered into
effective April 1, 2001 (the "Effective Date") by and between TheraSense, Inc.,
a Delaware corporation with a principal place of business at 1360 South Loop
Road, Alameda, California 94502, USA ("TheraSense") and Nipro Corporation, a
corporation organized under the laws of Japan, with a principal place of
business at 3-9-3, Honjo-Nishi, Kita-ku, Osaka, Japan ("Nipro").

                                  BACKGROUND

     A.   TheraSense is the owner of the FreeStyle Products (as defined below)
useful in monitoring blood glucose levels and desires to engage a marketing and
distribution partner which can (i) assist it in obtaining regulatory and
reimbursement approvals to market the FreeStyle Products, and (ii) promote,
market and distribute the FreeStyle Products; and

     B.   Nipro desires to purchase from TheraSense, and TheraSense desires to
sell to Nipro, the FreeStyle Products for resale in the Territory (as defined
below); and

     C.   Nipro desires to distribute and sell the FreeStyle Products to
Customers (as defined below) in the Territory.

     NOW, THEREFORE, in consideration of the mutual promises contained
herein, the parties agree as follows:

1.   DEFINITIONS

     1.1  "Affiliate" shall mean any corporation or other entity which is
           ---------
directly or indirectly controlling, controlled by or under common control with
TheraSense or Nipro. For the purpose of this Agreement, "control" shall mean the
direct or indirect ownership of fifty percent (50%) or more of the

<PAGE>

outstanding shares or other voting rights of the subject entity to elect
directors, or if not meeting the preceding, any entity owned or controlled by or
owning or controlling at the maximum control or ownership right permitted in the
country where such entity exists.

     1.2  "Competing Product" shall mean any system used for the measurement of
           -----------------
glucose levels for purposes of diagnosis, monitoring or treatment of diabetes
melitus.

     1.3  "Confidential Information" shall mean, subject to the provisions of
           ------------------------
Article 10 hereof, (i) any proprietary or confidential information or material
in tangible form disclosed hereunder that is marked as "Confidential" at the
time it is delivered to the receiving party, or (ii) proprietary or confidential
information disclosed orally hereunder which is identified as confidential or
proprietary when disclosed and such disclosure of confidential information is
confirmed in writing within thirty (30) days by the disclosing party.

     1.4  "Customers" shall mean Nipro's customers solicited by Nipro, its
           ---------
Affiliates or its Subdistributors within the Territory.

     1.5  "Field of Use" shall mean single use, disposable, in vitro tests for
           ------------
monitoring glucose in human body fluids. It is understood that Field of Use does
not include Strips intended for use with a continuous glucose monitoring system,
such as TheraSense's Messenger product.

     1.6  "FreeStyle Products(s)" shall mean those products intended for sale in
           ---------------------
the Territory, as listed in Exhibit A attached hereto. Subject to Section 2.3,
the Freestyle Products listed in Exhibit A may be changed, discontinued or added
to by TheraSense.

     1.7  "Kissei" shall mean the Kissei Pharmaceutical Corporation, a
           ------
corporation organized under the laws of Japan, with its principal place of
business at 19-48 Yoshino, Matsumoto, Nagano 399, Japan.

                                      -2-
<PAGE>

     1.8  "Subdistributor" shall mean a third party to whom Nipro has granted
           --------------
the right to distribute the FreeStyle Products under Section 2.2 hereof.

     1.9  "Territory" shall mean, as of the Effective Date, Japan.
           ---------

2.   FREESTYLE APPOINTMENT AND AUTHORITY OF NIPRO

     2.1  Appointment and Authority.
          -------------------------

          2.1.1  Exclusive Distributor. Subject to the terms and conditions
                 ---------------------
herein, TheraSense hereby appoints Nipro as TheraSense's exclusive and sole
distributor and marketing partner for the FreeStyle Products in the Territory in
the Field of Use, and Nipro hereby accepts such appointment. TheraSense agrees
not to sell the FreeStyle Products to anyone for delivery in the Territory in
the Field of Use or with knowledge that the FreeStyle Products are being
purchased for use or resale in the Territory in the Field of Use. Likewise,
Nipro agrees not to sell the Freestyle Products to anyone for delivery outside
the Territory, or inside the Territory outside the Field of Use, or with
knowledge that the FreeStyle Products are being purchased for use or resale
outside the Territory, or inside the Territory outside the Field of Use.

          2.1.2  Nipro's sole authority shall be to purchase FreeStyle Products
from TheraSense and to promote, market and resell such FreeStyle Products for
delivery to Customers in the Territory in the Field of Use in accordance with
the terms of this Agreement. Nipro shall not have the authority to make any
commitments whatsoever on behalf of TheraSense.

          2.1.3  Notwithstanding the rights granted to Nipro to distribute the
FreeStyle Products hereunder, Nipro shall have no right to advertise, solicit
sales, promote, market, sell or otherwise dispose of (i) the FreeStyle Products
outside the Territory, or (ii) any TheraSense products, other than the FreeStyle
Products in the Field of Use, in the Territory.

                                      -3-
<PAGE>

     2.2  Subdistributors. Subject to the provisions of this Section 2.2, Nipro
          ---------------
may appoint one or more third parties, with a reputation for competence and
ethical behavior, within any portion of the Territory to distribute the
FreeStyle Products in the Field of Use. Within twenty (20) days after the
appointment of such Subdistributor, Nipro shall notify TheraSense of the
identity of such Subdistributor. Nipro shall not sell or otherwise transfer the
FreeStyle Products to any Subdistributor until such Subdistributor enters into a
form of written agreement ("Subdistributor Agreement") with Nipro, binding the
Subdistributor to terms and conditions substantially similar to those terms and
conditions agreed upon by Nipro in this Agreement. Further, Nipro shall only
grant Subdistributors the right to make sales of the FreeStyle Products in the
Territory in the Field of Use. Nipro agrees to terminate a Subdistributor's
right to distribute the FreeStyle Products promptly upon becoming aware that
such Subdistributor, or its authorized distributor(s) or reseller(s), is selling
or otherwise distributing the FreeStyle Products in violation of its
Subdistributor Agreement. Each Subdistributor Agreement shall contain provisions
making TheraSense a direct and intended third party beneficiary of such
Subdistributor Agreement.

     2.3  FreeStyle Product Changes.
          -------------------------

          2.3.1  Changes in the FreeStyle Products. TheraSense shall notify
                 ---------------------------------
Nipro as soon as reasonably feasible of any intended material change,
discontinuation or addition to the FreeStyle Products supplied under this
Agreement. The features, function and/or appearance of any such FreeStyle
Product may be materially technically improved by TheraSense with three (3)
months prior written notice to Nipro so long as such improved product meets or
exceeds the Product Specification for such product, as listed in Exhibit E.
TheraSense may make non-material changes in such FreeStyle Products, including
without limitation changing components of a FreeStyle Product, without written
notice to Nipro. The Freestyle Products may be discontinued by TheraSense only
with Nipro's prior written consent, such consent not to be unreasonably
withheld.

                                      -4-

<PAGE>

          2.3.2  New Versions of the FreeStyle Products. TheraSense shall notify
                 --------------------------------------
Nipro as soon as reasonably feasible of any new versions of the FreeStyle
Products that TheraSense intends to make available for commercial sale in the
Territory (each a "New Version"); provided, it is understood and agreed that New
Versions shall not include any implantable glucose sensors developed and/or
commercialized by TheraSense. Upon TheraSense's notice to Nipro of the
availability of a particular New Version, the parties shall use their best
efforts to agree on transfer prices and other terms under which Nipro may obtain
the right to market and sell such New Version in the Territory. In the event the
parties are unable to agree on such terms within *** of TheraSense's notice to
Nipro, such New Versions shall not be added to this Agreement and TheraSense
shall be free to market and promote such New Version in the Territory; provided,
TheraSense shall not enter into a written agreement with or sell to any third
party to resell such New Version in the Territory for transfer prices and terms
more favorable to such third party than the final transfer prices and terms
rejected by Nipro.

          2.3.3  Implantable Glucose Sensors. TheraSense agrees to keep Nipro
                 ----------------------------
reasonably advised of TheraSense's progress with developing an implantable
glucose sensor, and in the event TheraSense intends to make such sensor
available for commercial sale in the Territory, TheraSense will provide Nipro an
opportunity to offer its distribution services in the Territory for such sensor,
which offer TheraSense is free to accept or reject without exception.

     2.4  Reservation of Rights. Except as expressly provided in this Article
          ---------------------
2, no right, title, or interest is granted, whether express or implied, by
TheraSense to Nipro, and nothing in this Agreement shall be deemed to grant to
Nipro rights in any products or technology other than the FreeStyle Products in
the Territory, nor shall any provision of this Agreement be deemed to restrict
TheraSense's right to exploit technology, know-how, patents, or any other
intellectual property rights relating to the FreeStyle Products in products
other than the FreeStyle Products in the Territory. TheraSense reserves the
right to appoint other authorized distributors or resellers outside the
Territory provided that they are prohibited

                                      -5-

*** Confidential treatment requested
<PAGE>

from selling or delivering FreeStyle Products in the Territory. TheraSense
agrees to terminate a distributor or reseller's right to distribute FreeStyle
Products promptly upon becoming aware that the distributor or reseller is
selling or distributing the FreeStyle Products, directly or indirectly, in the
Territory. TheraSense also reserves the right to appoint third parties to
distribute the FreeStyle Products and New Versions inside the Territory in
fields of use other than the Field of Use. It is further understood and agreed
that TheraSense may distribute products, other than the FreeStyle Products, in
the Territory, either directly or indirectly, for any and all uses. In addition
TheraSense reserves the right to sell Strips in the Territory, either directly
or through third parties, solely for use in calibrating a continuous glucose
monitoring system ("CGMS"), provided TheraSense will only market and sell such
Strips for use with such CGMS. ***

     2.5  Conflict of Interest. During the term of this Agreement, Nipro agrees
          --------------------
not to promote, market, or sell a Competing Product in the Field of Use in the
Territory.

     2.6  Independent Contractors. The relationship of TheraSense and Nipro
          -----------------------
established by this Agreement is that of independent contractors, and nothing
contained in this Agreement shall be construed to (i) give either party the
power to direct and control the day-to-day activities of the other, (ii)
constitute the parties as partners, joint venturers, co-owners or otherwise as
participants in a joint venture or common undertaking, or (iii) allow either
party to create or assume any obligation on behalf of the other for any purpose
whatsoever. All financial and other obligations associated with either party's
business are the sole responsibility of the party.

                                      -6-

*** Confidential treatment requested
<PAGE>

3.   CONSIDERATION

     3.1  Signature Payments. In partial consideration of the distribution
          -------------------
rights granted herein, upon the Effective Date of this Agreement, Nipro shall
pay to TheraSense a nonrefundable (except as provided for in Section 12.6.2),
noncreditable payment of Five Million U.S. Dollars (U.S. $5,000,000).

     3.2  TheraSense Product Prices.
          -------------------------

          3.2.1  TheraSense Products. For each FreeStyle Product purchased from
                 -------------------
TheraSense, Nipro shall pay to TheraSense an amount equal to the transfer price
set forth in Exhibit B (the "Transfer Price"). All prices are in U.S. Dollars
with terms FCA (Incoterms 2000) the Shipping Location (as defined in Section 5.5
below). The difference between the Transfer Price and Nipro's price to its
Customers shall be Nipro's sole remuneration for distribution of the FreeStyle
Products. The Transfer Prices set forth in Exhibit B shall remain in effect from
the Effective Date *** of the Effective Date. Thereafter, TheraSense has the
right to *** revise the Transfer Prices with *** advance written notice to
Nipro; provided, any such increase shall not *** averaged over the preceding
calendar year.  Such revisions shall apply to all orders received after the
effective date of revision.

          3.2.2  Transfer Price Adjustments. By December 1 of each calendar year
                 --------------------------
Nipro shall provide to TheraSense a non-binding written estimate of its
requirements of Strips (as defined in Exhibit A) for the upcoming calendar year
(the "Estimated Annual Volume"). The Estimated Annual Volume shall be used to
establish the Transfer Price for the Strips for the first quarter of the
upcoming year. Thereafter, upon Nipro's submission of each quarterly forecast to
TheraSense, if either party concludes that the annual purchase of Strips will be
higher or lower than the Estimated Annual Volume so as to cause a different
Transfer Price to obtain, the parties will agree on a price change for Strips
for future shipments in such quarter. The objective of each quarterly price
change will be to minimuze year-end credits or rebates between the parties.

                                      -7-

*** Confidential treatment requested
<PAGE>

Notwithstanding the foregoing, in no event shall Nipro be obligated to pay,
or TheraSense be entitled to receive, more or less than the corresponding amount
set forth on Exhibit B for the actual number of Strips purchased by Nipro in
each calendar year. Within 30 days after the end of each calendar year, Nipro or
TheraSense shall pay to the other any amounts due relating to underpayments
accrued or overpayments made with respect to the Strips in such calendar
year.

          3.2.3  Government Reimbursements. The parties recognize that the
                 -------------------------
market price for Strips in the Territory may change up or down as a result of
changes in the Japan government reimbursement policies. Nipro shall promptly
inform TheraSense in writing, documenting any such changes in the reimbursement
policies for hospital or clinic blood glucose testing which would affect the
price Nipro would actually receive for sales of Strips. ***.

          3.2.4  Payment for TheraSense Products. TheraSense shall submit an
                 -------------------------------
invoice to Nipro upon each shipment of FreeStyle Products ordered by Nipro and
as set forth below in Section 5.5. The invoice shall cover the Transfer Price
for the FreeStyle Products in a given shipment plus any freight, taxes or other
costs incident to the purchase or shipment initially paid by TheraSense but to
be borne by Nipro. The invoiced amounts for FreeStyle Products shipped shall be
due in full net thirty (30) days upon the later of receipt by Nipro of the
FreeStyle Products or the invoice.

                                      -8-

*** Confidential treatment requested
<PAGE>

          3.2.5  Delinquency. In the event that Nipro's account becomes
                 -----------
***.

     3.3  Payment Method. Nipro shall make payments to TheraSense under this
          --------------
Agreement by wire transfer to a bank account designated by TheraSense. All
payments due hereunder shall be paid in U.S. dollars.

4.   SUPPLY OF PRODUCTS; PACKAGING AND LABELING

     4.1  Supply of FreeStyle Products. Subject to terms of this Agreement,
          ----------------------------
including without limitation Article 5, TheraSense shall sell the FreeStyle
Products (Meters, Strips (pre-packaged in vials and boxes), Lancing Devices and
Control Solution (each as defined in Exhibit A)) to Nipro in bulk.

     4.2  Supply of Lancets. Nipro shall be responsible for obtaining the
          -----------------
lancets (a disposable head placed in the Lancing Device for use in piercing the
skin of the patient to be tested, each a "Lancet") to be used in conjunction
with the FreeStyle Products. Lancets obtained by Nipro shall meet mutually
agreed upon specifications.

     4.3  Product Packaging and Labeling.
          ------------------------------

          4.3.1  Strip Packaging and Labeling. Strips shall be delivered to
                 ----------------------------
Nipro pursuant to Section 5.4 below, in a package, including without limitation
vials or boxes, (the "Strip Package") containing the Strips together with an
insert. Both the Strip Package and the insert shall be labeled as follows:
"Manufactured by TheraSense" and "Distributed by Nipro" and shall carry both the
TheraSense and Nipro logo (or at Nipro's prior reasonable notice and election,
Nipro's name and logo shall be

                                      -9-

*** Confidential treatment requested
<PAGE>

replaced by "Kissei"). Unless otherwise instructed by TheraSense in writing,
Nipro shall deliver the Strips to its Customers only as part of an unopened
Strip Package.

          4.3.2  Product, Packaging and Labeling. Nipro shall be responsible for
                 -------------------------------
packaging and labeling (including without limitation any final packaging and
labeling), (i) each FreeStyle Product (other than the Strip Package) supplied to
Nipro by TheraSense hereunder, (ii) the Lancets, and (iii) all printed materials
to be inserted within or upon such packaging, in each case, subject to
TheraSense's prior review and written approval, such approval not to be
unreasonably withheld (the "Packaging Materials"). Once a particular Packaging
Material has been approved by TheraSense, it may be used by Nipro without
further approval from TheraSense. Nipro shall be also responsible for ensuring
that all FreeStyle Products and Lancets are packaged and labeled in accordance
with the requirements of all applicable regulatory authorities in Japan,
including without limitation the requirements set forth by the Japan Ministry of
Health and Welfare ("JMHW"). Except for the addition of information required by
applicable laws and regulations, Nipro shall not re-label FreeStyle Products
supplied to Nipro by TheraSense hereunder without the prior written consent of
TheraSense.

     4.4  Proprietary Notices.
          -------------------

          4.4.1  Marking. All FreeStyle Products and their Packaging Materials
                 -------
distributed by Nipro in the Territory shall be marked with any appropriate
patent number, TheraSense's name and trademarks ("Trademarks", as listed in
Exhibit D) and the name of either Nipro or Kissei; provided, the Strips
contained within the Strip Package shall only be marked with TheraSense's
Trademark(s). FreeStyle Products and their Packaging Materials shall be marked
with TheraSense Trademarks in at least equal prominence to Nipro's marks. Nipro,
its Affiliates and its Subdistributors shall not remove, alter, cover or
obfuscate any of the Trademarks or other proprietary rights notices placed or
embedded by TheraSense on any FreeStyle Product or Strip Package or any of the
items contained therein. TheraSense

                                      -10-
<PAGE>

reserves the right to modify the Trademarks or substitute alternative marks for
any or all of the Trademarks at any time ***. In addition, Nipro agrees to use
those Trademarks in connection with the FreeStyle Products as may be directed in
writing by TheraSense.

             4.4.2  Use. During the term of this Agreement, Nipro may indicate
                    ---
to the public that it is an authorized distributor of the FreeStyle Products and
to advertise and promote to Customers (within the Territory) the FreeStyle
Products under the Trademarks.

             4.4.3  Approval of Representations. All representations of the
                    ---------------------------
Trademarks that Nipro intends to use shall first be submitted to TheraSense for
approval (which shall not be unreasonably withheld) of design, color, and other
details or shall be exact copies of those used by TheraSense. Nipro agrees to
fully comply with all reasonable guidelines communicated by TheraSense
concerning use of its Trademarks. Nipro may not mark the FreeStyle Products, the
Strip Package or their Packaging Materials with the Trademarks of any third
party, other than Kissei, without the prior written consent of TheraSense; which
consent shall not be unreasonably withheld. If any of TheraSense's Trademarks
are to be used in conjunction with another trademark on or in relation to the
FreeStyle Products, Strip Package or their Packaging Materials, then the
Trademarks shall be presented at least equally legibly, equally prominently, and
of equal or greater size than the other but nevertheless separated from the
other so that each appears to be a mark in its own right, distinct from the
other mark.

             4.4.4  Retained Rights. Nipro acknowledges that the requirement
                    ---------------
that the Trademarks appear on all packages and only in accordance with
TheraSense's directions are intended to ensure that all of the goodwill created
by the marketing and use of the FreeStyle Products in the Territory will accrue
for the benefit of TheraSense and that all use of the Trademarks, and any
goodwill associated therewith, shall inure to TheraSense. Nothing contained in
this Agreement shall grant to Nipro any right, title or interest in the
Trademarks, whether or not specifically recognized or perfected under applicable
laws, and

                                      -11-

*** Confidential treatment requested
<PAGE>

Nipro irrevocably assigns to TheraSense all such right, title, and interest, if
any, in any Trademarks. Without limiting the foregoing, TheraSense shall retain
the worldwide right to use such Trademarks for its own co-marketing efforts and
for the distribution/sale of other products. At no time during or after the term
of this Agreement shall Nipro challenge or assist others to challenge the
Trademarks or the registration thereof or attempt to register any trademarks,
marks or trade names confusingly similar to those of TheraSense.

5.       TERMS OF PURCHASE OF FREESTYLE PRODUCTS BY NIPRO

         5.1  Solicitation and Placement of Orders from Customers. Nipro shall
              ---------------------------------------------------
be responsible for marketing and soliciting orders for FreeStyle Products from
Customers in the Territory, in the Field of Use.

         5.2  Terms and Conditions. All orders of FreeStyle Products by Nipro
              --------------------
from TheraSense during the term of this Agreement shall be subject to the terms
of this Agreement. Nothing contained in any purchase order, order
acknowledgement, or like document submitted by either party to the other shall
in any way modify or add to the terms and conditions in this Agreement.

         5.3  Forecasts. Beginning on the Effective Date and thereafter ***
              ---------
Nipro shall provide to TheraSense a good faith, non-binding written forecast of
the number of units of FreeStyle Products that Nipro expects to purchase ***
("Forecasts"). Subject to Section 5.4 below, the parties acknowledge that the
Forecasts are for TheraSense's planning purposes only and shall not be binding
upon the parties. Nipro and TheraSense shall meet, by telephone or in person, no
less frequently than *** to review Forecasts.

         5.4  Order and Acceptance. On a month-to-month and FreeStyle
              --------------------
Product-by-FreeStyle Product basis, Nipro shall submit orders for units of
FreeStyle Products so that such orders are received

                                      -12-

*** Confidential treatment requested
<PAGE>

by TheraSense *** prior to its requested date of receipt of such units of
FreeStyle Products. Unless otherwise mutually agreed, Nipro shall be obligated
to purchase each month *** the amount of FreeStyle Products forecasted for such
month in its current Forecast ("Binding Forecasts"). No order shall be binding
upon TheraSense until accepted by TheraSense in writing but TheraSense agrees to
accept Nipro's purchase orders for quantities of FreeStyle Products ordered by
Nipro in a month *** the Binding Forecast for such month. Once accepted by
TheraSense, Nipro may cancel or reschedule purchase orders for FreeStyle
Products only with TheraSense's prior written approval. Nipro will use
commercially reasonable efforts to place orders for FreeStyle Products in an
even and regular fashion so as to allow for efficient scheduling of FreeStyle
Products production and warehousing. In the event TheraSense receives a purchase
order *** in advance of the requested receipt date or for a quantity that is ***
the Binding Forecast for a month, TheraSense will use commercially reasonable
best efforts to ship such FreeStyle Products to Nipro on the date and in the
quantity requested by Nipro; provided, TheraSense shall have no liability to
Nipro with respect to such orders that do not meet the requirement of this
Section 5.4 and are not accepted by TheraSense.

         5.5  Shipping. All FreeStyle Products delivered pursuant to the terms
              --------
of this Agreement shall be suitably packed in TheraSense's standard shipping
cartons, and marked for shipment at the address of Nipro, as provided in Nipro's
purchase order, for delivery within ten (10) days (excluding weekends) to Nipro,
FCA (Incoterms 2000) TheraSense's facility currently located at the address
listed for TheraSense in Article 16 of this Agreement or such other location as
TheraSense may designate (the "Shipping Location"), at which time risk of loss
shall pass to Nipro. All expenses related to shipment from the United States to
Japan, including without limitation, exportation and importation fees, customs
duties and tariffs, freight, insurance, and other shipping expenses, as well as
any special packing expense, shall

                                      -13-

*** Confidential treatment requested
<PAGE>

be paid by Nipro. Nipro shall have the right to specify a carrier at the time it
places its order but, if it does not do so, TheraSense may choose the mode of
shipment and carrier.

         5.6  Acceptance of FreeStyle Products. TheraSense shall certify that
              --------------------------------
each shipment of FreeStyle Products meets the product specifications listed in
Exhibit E (the "Product Specifications"). Nipro shall have the right to inspect
all FreeStyle Products promptly upon receipt thereof for conformance with the
Product Specifications. Any FreeStyle Products not rejected by Nipro within
thirty (30) days will be deemed accepted. TheraSense will, at its election,
either repair or replace rejected defective FreeStyle Products within thirty
(30) days of receipt thereof. In the event Nipro rejects any FreeStyle Products,
Nipro shall be required to demonstrate that such product does not meet a
commercially material specification set forth in Exhibit E. The warranty for
such products shall continue independent of such acceptance or rejection.

6.       WARRANTY

         6.1  Warranty to Customer. Any warranty set forth in this Section 6.1
              --------------------
shall run directly from TheraSense to Customers. Subject to this Section 6.1,
TheraSense shall promptly replace any FreeStyle Product that does not meet one
or more of its warranties.

              6.1.1 Nipro Obligations. Nipro shall have responsibility for
                    -----------------
handling Customer returns for non-conforming FreeStyle Products under the
warranty. TheraSense shall refer all Customer warranty issues to Nipro for
resolution. Nipro shall make no warranties with respect to any of the FreeStyle
Products that exceed the warranty made by TheraSense. In the event TheraSense is
unable to replace at its expense a faulty product, TheraSense's sole and
exclusive liability and Nipro's exclusive remedy shall be to credit Nipro's
account for Nipro's original landed cost for the FreeStyle Product or, in the
case of Nipro packaged FreeStyle Product, the inventory value according to
Nipro's inventory

                                      -14-
<PAGE>

accounting or, in the case of FreeStyle Products returned by a Customer, in
accordance with Section 6.1.5.

             6.1.2  TheraSense Limited Warranty. TheraSense warrants to
                    ---------------------------
Customers that upon delivery, FCA the shipping location, and during the warranty
period for the FreeStyle Products, as set forth on the product label and/or
insert (as provided by TheraSense), FreeStyle Products: (i) will meet the agreed
upon Product Specifications as set forth in Exhibit E, (ii) will be free from
defects in design, materials and workmanship, (iii) will be of merchantable
quality and fit for the purpose for which they are intended, and (iv) will
comply with all applicable laws in the place of manufacture.

             6.1.3  Warranty Limitations. The warranties in Sections 6.1.1 and
                    --------------------
6.1.2 shall not apply to FreeStyle Products that have been modified or altered
in any manner by anyone other than by or on behalf of TheraSense, or to defects
caused (i) through no fault of TheraSense during shipment to or from Nipro; (ii)
by the use or operation in an application or environment other than that
intended or recommended by TheraSense; (iii) by service by anyone other than
employees of, or persons approved in writing by, TheraSense; (iv) by accident,
negligence, misuse, other than normal electrical stress, or other causes other
than normal use; or (v) by storage, usage or handling in any manner inconsistent
with the FreeStyle Products label provided by TheraSense. Replacement FreeStyle
Products supplied under this warranty shall carry only the unexpired portion of
the original warranty. TheraSense shall not be liable for misbranding with
respect to any product labeling or package insert text provided or used by
Nipro, or any translation thereof and TheraSense shall not be liable for any
adulteration or failure to meet the Product Specifications due to handling or
packaging of the FreeStyle Products by Nipro, its Affiliates, its
Subdistributors or agents.

             6.1.4  Exclusion of Other Warranties. EXCEPT FOR THE LIMITED
                    -----------------------------
WARRANTIES PROVIDED IN SECTIONS 6.1.1, 6.1.2 AND 6.1.3 ABOVE, THERASENSE GRANTS
NO OTHER

                                      -15-
<PAGE>

WARRANTIES OR CONDITIONS, EXPRESS OR IMPLIED, BY STATUTE, IN ANY COMMUNICATION
WITH NIPRO OR ITS CUSTOMERS, OR OTHERWISE, REGARDING THE FREESTYLE PRODUCTS, AND
THERASENSE SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTIES OF FITNESS FOR A
PARTICULAR PURPOSE, MERCHANTABILITY, AND NONINFRINGEMENT. EXCEPT AS PROVIDED
EXPRESSLY IN THIS AGREEMENT AND/OR THERASENSE'S WARRANTY, THERASENSE DOES NOT
WARRANT THAT OPERATION OF THE FREESTYLE PRODUCTS WILL BE UNINTERRUPTED OR ERROR-
FREE. THERASENSE NEITHER ASSUMES NOR AUTHORIZES ANY OTHER PERSON TO ASSUME ANY
OTHER LIABILITIES ARISING OUT OF OR IN CONNECTION WITH THE SALE OR USE OF ANY
FREESTYLE PRODUCT. ANY OTHER REPRESENTATIONS OR WARRANTIES MADE BY ANY PERSON OR
ENTITY, INCLUDING EMPLOYEES OR REPRESENTATIVES OF THERASENSE, THAT ARE
INCONSISTENT HEREWITH SHALL BE DISREGARDED AND SHALL NOT BE BINDING UPON
THERASENSE OR ITS THIRD PARTY SUPPLIERS.

             6.1.5  Limitation of Liability. THERASENSE'S LIABILITY UNDER ITS
                    -----------------------
CUSTOMER WARRANTY SHALL BE LIMITED TO A REFUND OF THE CUSTOMER'S PURCHASE PRICE
TO NIPRO, IN WHICH CASE NIPRO WILL REFUND SUCH AMOUNT TO THE CUSTOMER, AND A
REFUND OF NIPRO'S SHIPPING COSTS WITH RESPECT TO THE DEFECTIVE FREESTYLE
PRODUCT. IN NO EVENT SHALL THERASENSE BE LIABLE TO NIPRO OR ANY THIRD PARTY FOR
LOST PROFITS, THE COST OF PROCUREMENT OF SUBSTITUTE GOODS BY THE CUSTOMER, OR
FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES FOR BREACH OF
WARRANTY. THIS LIMITATION SHALL APPLY EVEN WHERE THERASENSE HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGE AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL
PURPOSE OF ANY LIMITED REMEDY STATED HEREIN.

                                      -16-
<PAGE>

         6.2  Representation and Warranties by and between Nipro and TheraSense.
              -----------------------------------------------------------------

              6.2.1  Warranty to TheraSense. Nipro represents and warrants to
                     ----------------------
TheraSense that: (i) it is a corporation duly organized validly existing and in
good standing under the laws of Japan; (ii) the execution, delivery and
performance of this Agreement have been duly authorized by all necessary
corporate action on the part of Nipro.

              6.2.2  Warranty to Nipro. TheraSense represents and warrants to
                     -----------------
Nipro that: (i) it is a company duly organized validly existing and in good
standing under the laws of the State of Delaware; (ii) the execution, delivery
and performance of this Agreement have been duly authorized by all necessary
corporate action on the part of TheraSense; (iii) it has the right to grant
Nipro the exclusive distribution rights in the Territory as specified in Section
2.1.1 and, to the best of its knowledge, it has the right to grant the other
rights granted herein; and (iv) subject to Sections 6.1.3 and 6.1.4, upon
delivery, FCA the Shipping Location, the Freestyle Products will (a) meet the
agreed upon Product Specifications as set forth in Exhibit E, (b) will be free
from defects in manufacturing, materials and workmanship, (c) will be of
merchantable quality and fit for the purpose for which they are intended, and
(d) will comply with all applicable laws in the place of manufacture.

7.       ADVERTISING, MARKETING AND PROMOTION

         7.1  Advertising and Promotions. Nipro, its Affiliates and
              --------------------------
Subdistributors shall bear all expenses associated with the marketing, sales and
customer support of the FreeStyle Products in the Territory. Promptly upon
receipt of all necessary Approvals (as defined in Section 8.1), Nipro shall, at
its own expense, (i) use commercially reasonable efforts to promote the sale and
distribution of the FreeStyle Products to Customers in the Territory, and (ii)
use commercially reasonable efforts to realize the maximum sales potential for
the FreeStyle Products to Customers in the Territory. Such commercially
reasonable efforts by Nipro may include without limitation the following:

                                      -17-
<PAGE>

             (a) maintenance of an adequate and experienced sales force;

             (b) dedication of sufficient product and project management,
marketing and customer support resources to pursue the market opportunities for
the product in the Territory;

             (c) the preparation of promotional aids and materials;

             (d) the translation of clinical, technical, packaging, advertising,
and promotional materials into the primary language(s) within the Territory;
provided, however, that TheraSense shall own all rights in and to such
translations, subject to the Translation Repayment (as defined in Section 7.2.2
below);

             (e) advertising the FreeStyle Products in professional and consumer
publications within the Territory;

             (f) participating in congresses, symposia, and exhibitions within
the Territory;

             (g) systematically identifying and targeting key customers and
making sales calls on such customers within the Territory.

             (h) sponsoring technical papers and presentations.

             (i) organization of user panels to provide insight into customer
decision making.

In addition to the foregoing, Nipro shall (i) use reasonable efforts, at its own
expense, to maintain a sufficient inventory of FreeStyle Products and to fulfill
forecast demand for FreeStyle Products within

                                      -18-
<PAGE>

the Territory; and (ii) act so as to establish and maintain a favorable
reputation of the FreeStyle Products and marks in the Territory.

         7.2  Nipro Materials.
              ---------------

              7.2.1  Nipro Materials. Nipro shall provide to TheraSense for
                     ---------------
purposes of review, comment and approval by TheraSense, English language
translations of any and all promotional, advertising and educational materials
and programs, package data sheets, and other literature relating to the
FreeStyle Products at least fifteen (15) days prior to the commercial release of
such materials or commencement of such programs for the purpose of: (i) enabling
TheraSense to comply with regulations applicable to such materials; and (ii)
ensuring that such materials correspond with TheraSense's product policies.

              7.2.2  Effect of Termination. It is recognized that Nipro shall
                     ---------------------
experience significant expenses related to the translation of materials for
clinical, technical, packaging, advertising, and promotional reasons. Upon
expiration or any termination of this Agreement. TheraSense shall have all
rights to take over and use the translations made by Nipro, and Nipro shall
fully cooperate with TheraSense to make such translations available for the free
and full use by TheraSense or its agent, subject to the following:

                    (a) in the event this Agreement is terminated by Nipro due
to TheraSense's material breach, or in the event TheraSense elects not to extend
the term of this Agreement pursuant to Section 12.1.2, or in the event
TheraSense terminates this Agreement for Nipro's failure to meet the Annual
Minimum Purchase Obligations (as defined in Section 8.5) in any year, TheraSense
shall pay Nipro the cost of such translations, up to a maximum amount *** (the
"Translation Repayment"), as evidenced by copies of the invoices for such
translation which Nipro will provide TheraSense no later than six (6) months
from the Effective Date; or

                                      -19-

*** Confidential treatment requested

<PAGE>

                   (b) in the event this Agreement is terminated by TheraSense
due to Nipro's material breach, or in the event Nipro elects not to extend the
term of this Agreement pursuant to Section 12.1.2, TheraSense shall have no
obligation to pay the Translation Repayment.

         7.3  TheraSense Collaboration. TheraSense will collaborate with Nipro
              ------------------------
in the development of all marketing and promotional materials. TheraSense will,
at its own expense, provide Nipro with:

              7.3.1 such marketing and technical assistance and promotional
materials (in English) as TheraSense may in its reasonable discretion consider
necessary to assist with the promotion of the FreeStyle Products;

              7.3.2 training for Nipro's personnel in connection with the
marketing, sale, installation, maintenance and support of the FreeStyle Products
during the *** period following the Effective Date; provided, TheraSense's
personnel shall spend *** in providing such training unless the parties agree to
provide additional training;

              7.3.3 reasonable access to TheraSense support personnel by Nipro's
support personnel to assist Nipro in providing customer support.

8.       ADDITIONAL OBLIGATIONS OF NIPRO

         8.1  Registrations, Licenses and Permits.
              -----------------------------------

              8.1.1 If and as required from time to time under the laws of the
Territory, Nipro, at Nipro's expense, shall perform clinical trials and obtain
all registrations, licenses, permits, import approvals, reimbursement approvals,
and other legal or administrative items required to comply with the laws and
regulations of the Territory for importation, sale and distribution of the
FreeStyle Products, and gain reimbursement for such sales (collectively
"Approvals"). Nipro shall provide to TheraSense, for

                                      -20-

*** Confidential treatment requested
<PAGE>

TheraSense's unrestricted use, complete copies of all clinical trials,
protocols, data, analyses and other information, as well as applications, and
all registrations, licenses, permits, and approval obtained therefrom relating
to the FreeStyle Products.

             8.1.2 TheraSense will provide Nipro with all information, data,
materials and product samples in its possession necessary to obtain Approvals.
In the event that disclosure of TheraSense trade secrets are required for the
Approvals, TheraSense will provide such trade secret information directly to the
Japan regulatory authorities.

             8.1.3 All Approvals will be in Nipro's name unless otherwise agreed
by the parties or required by law. Upon the expiration, cancellation, or
termination of this Agreement, Nipro shall transfer such Approvals to TheraSense
or TheraSense's agent so that TheraSense will be able to continue to sell
FreeStyle Products and be reimbursed for FreeStyle Products in the Territory,
subject to the following:

                   (a) in the event this Agreement is terminated by Nipro due to
TheraSense's material breach, or in the event TheraSense elects not to extend
the term of this Agreement pursuant to Section 12.1.2, or in the event
TheraSense terminates this Agreement for Nipro's failure to meet the Annual
Minimum Purchase Obligations in any year, TheraSense shall pay Nipro *** to
compensate Nipro for the direct expenses paid by Nipro to obtain and transfer
such Approvals (the "Approval Compensation"); or

                   (b) in the event this Agreement is terminated by TheraSense
due to Nipro's material breach, or in the event Nipro elects not to extend the
term of this Agreement pursuant to Section 12.1.2, TheraSense shall have no
obligation to pay the Approval Compensation.

                                      -21-

*** Confidential treatment requested
<PAGE>

         8.2  Health and Safety Laws and Regulations. In performing its
              --------------------------------------
obligations under this Agreement, Nipro shall comply fully with any and all
applicable health and safety laws and regulations of the Territory as they
relate to the FreeStyle Products. In addition, Nipro shall monitor the
appropriate information sources closely for changes in such laws and
regulations, and other requirements in the Territory relating to the
distribution of the FreeStyle Products in the Territory, and notify TheraSense
promptly in writing of any and all such changes.

         8.3  Sales and Inventory Records. Nipro agrees to maintain a sales and
              ---------------------------
inventory record showing, at a minimum, date sold, quantity, serial number or
lot number, shipment information, and the buyers' names and addresses of each of
the FreeStyle Products sold, as well as the quarter-end inventory position on
hand for each of the FreeStyle Products. Such records shall be kept at Nipro's
principal place of business for at least three (3) years following the end of
the calendar quarter to which they pertain. This information shall be made
available to TheraSense at TheraSense's request solely to satisfy ISO
certification, regulatory, and/or administrative requirements.

         8.4  Sales Reports. At the end of each calendar quarter, Nipro will
              -------------
provide TheraSense with a quarterly report including the following information:

              (a) monthly net sales in units of Meters to Customers in the
Territory;

              (b) monthly net sales in units of Strips to Customers in the
Territory

              (c) monthly net sales in Yen of FreeStyle Products other than
Meters and Strips to Customers in the Territory;

              (d) reporting of monthly Meter placements (units) made free of
charge to Customers;

                                      -22-
<PAGE>

Nipro shall also include in this quarterly report a description of any
developments regarding the market, competitors, government authorities, or other
material developments which Nipro judges to be of importance to the success of
FreeStyle Products, or otherwise important for TheraSense to know.

         8.5  Annual Minimum Purchase Obligations. Nipro shall purchase no less
              -----------------------------------
than the amount of Strips listed on Exhibit C for sale in the Territory in each
calendar year (the "Annual Minimum Purchase Obligations"). TheraSense shall have
the right, at its option, to terminate this Agreement for cause pursuant to
Section 12.2 hereof, in the event that ***.

         8.6  Books and Records. At TheraSense's request, Nipro, its Affiliates,
              -----------------
and its Subdistributors agree to furnish a full and detailed statement of such
party's business and operations (but only to the extent it relates to the Nipro
relationship created hereby), including, without limitation, any and all sales
and inventory records required to be kept pursuant to this Agreement, but solely
to satisfy ISO certification, regulatory, and/or administrative requirements.

         8.7  Business Review; Semi-Annual Business Plans.
              -------------------------------------------

              8.7.1 Semi-Annual Business Plans. TheraSense and Nipro shall meet,
                    --------------------------
in person, no less frequently than once every six months to review Nipro's
business plan for marketing and distributing the FreeStyle Products in the
Territory. Such business plan shall include, without limitation, promotion
strategy and tactics, and sales and other marketing plans. TheraSense shall have
the right to review and comment on such business plan.

                                      -23-

*** Confidential treatment requested
<PAGE>

              8.7.2 Business Review. The parties will meet at least annually to
                    ---------------
review developments in the marketplace, including pricing, competitive
developments, regulatory and administrative changes, and other factors important
to success of the FreeStyle Products in the Territory.

         8.8  Customer Support. Nipro shall maintain knowledgeable sales,
              ----------------
marketing, and support personnel to provide instructions to Customers in the
Territory in the use of the FreeStyle Products. Upon Nipro's request, TheraSense
shall provide a reasonable level of assistance with technical information and
training of Nipro and Kissei employees for the FreeStyle Products. Any expenses
related to such activities shall be borne by Nipro.

         8.9  Medical Device Reporting.
              ------------------------

              8.9.1 Reporting. Pursuant to governmental medical device reporting
                    ---------
regulations (e.g. the FDA's Medical Device Reporting (MDR) Regulations, the
European Medical Device Vigilance Guidelines, and any other applicable medical
device reporting regulations in Japan), TheraSense is required to report to the
applicable agency information that reasonably suggests that the FreeStyle
Products may have caused or contributed to a death or serious injury or has
malfunctioned and that the device would be likely to cause or contribute to a
death or serious injury if the malfunction were to recur. Each of TheraSense and
Nipro agree to supply to the other any such information promptly after becoming
aware of it so that each of TheraSense and Nipro can comply with governmental
reporting requirements.

             8.9.2  Recall Cooperation. In the event of any potential recall of
                    ------------------
FreeStyle Product in the Territory, Nipro will consult with TheraSense as to the
actions which shall be taken with respect to Customers and with respect to
government authorities in implementing such recall, including without
limitation, in locating, and retrieving if necessary, recalled FreeStyle
Products from Customers. Nipro and TheraSense shall reach agreement on such
actions prior to the product recall implementation;

                                      -24-
<PAGE>

provided, neither party shall unreasonably withhold agreement to such actions,
and the parties shall observe all legal and regulatory requirements which apply
to such recall.

             8.9.3  Recall Expenses. In the event of a recall of a FreeStyle
                    ---------------
Product, whether required or voluntary, the recall shall be at Nipro's cost and
expense in the Territory and at TheraSense's cost and expense outside the
Territory. Notwithstanding the foregoing, in the event that a recall is
primarily due to a manufacturing defect in the FreeStyle Products which requires
the replacement of FreeStyle Products, then TheraSense shall provide to Nipro
replacement FreeStyle Products free of charge.

             8.9.4  Records. Nipro shall maintain records of sales of FreeStyle
                    -------
Products by lot number and by third-party (including without limitation
distributors, wholesalers, and retailers) to whom such product was sold or
otherwise transferred. Upon TheraSense's request, Nipro shall provide TheraSense
with access to such records in the event of a FreeStyle Products recall or other
quality related issue. Nipro shall be responsible for obtaining all records of
its sales to end users in the event of a FreeStyle Products recall or other
quality related issue. Nipro shall make available to TheraSense for inspection
Nipro's process and records for adverse event and other regulatory reporting
purposes at mutually agreed upon times and further shall ensure that Nipro's
processes comply with all applicable laws and regulations in the Territory.

       8.10  Product Complaints. Nipro shall promptly investigate and monitor
             ------------------
all Customer and/or regulatory complaints and/or correspondence concerning the
use of the FreeStyle Products in the Territory. Nipro shall use commercially
reasonable efforts to advise TheraSense of all complaints alleging patient
injury promptly, if possible within twenty four (24) hours, but not more than
five (5) days business days following the date Nipro receives such complaint,
and of all other complaints relating to the FreeStyle Products as promptly as
possible but not more than five (5) business days following the date Nipro
receives such complaint. In addition, within fifteen (15) calendar days
following the date

                                      -25-
<PAGE>

Nipro receives such complaint, Nipro shall also provide TheraSense with a
materially complete written report relating thereto. Any notice to TheraSense
under this Section 8.10 shall be sent via facsimile and overnight delivery
service to the attention of TheraSense's Vice President of Regulatory Affairs or
to such other address or person as TheraSense may designate by notice.

         8.11  Notification of Unauthorized Use. Nipro shall promptly notify
               --------------------------------
TheraSense in writing upon its discovery of any unauthorized use or infringement
of the FreeStyle Products and/or TheraSense's patent, copyright, trademark or
other intellectual property rights with respect thereto. TheraSense shall have
the sole and exclusive right to bring an infringement action or proceeding
against a third party, but TheraSense shall use its commercially reasonable
judgment in determining its enforcement actions. In the event that TheraSense
brings such an action or proceeding, Nipro shall provide commercially reasonable
cooperation and provide commercially reasonable information and assistance to
TheraSense and its counsel in connection with any such action or proceeding;
provided that TheraSense shall reimburse Nipro for any direct costs (such as
reasonable attorney's fees) incurred by Nipro.

         8.12  Nipro Improvements.
               ------------------

               8.12.1 In the event that Nipro makes a commercially important
improvement to the FreeStyle Products (an "Improvement"), then TheraSense shall
have a "right of first refusal" to negotiate the rights to such improvement on
commercially reasonable terms. ***.

               8.12.2 Prior to offering an Improvement to a third party, Nipro
shall offer the Improvement to TheraSense by providing TheraSense with at least
the same level of information that

                                      -26-

*** Confidential treatment requested
<PAGE>

Nipro would provide to any third party. TheraSense shall *** review such
information and provide written notification to Nipro regarding its decision to
enter into negotiations for the right to such Improvement. If written notice is
given that TheraSense does not want to enter into negotiations for a license, or
written notice is not given by TheraSense within said *** period, TheraSense
will have waived its right of first refusal to license the applicable
Improvement, and Nipro will be free to license such Improvement to any third
party without further obligation to TheraSense. If TheraSense provides written
notice of its desire to enter into negotiations, the parties shall have a ***
period from the date of TheraSense's notice to Nipro to conclude a definitive
license agreement in good faith with respect to the applicable Improvement. If
the parties cannot conclude an agreement in said *** timeframe, and do not
mutually agree to extend such negotiation period, Nipro shall be free to license
such Improvement to any third party, as long as the terms of such license are
not materially better than those offered to TheraSense.

9.       ADDITIONAL OBLIGATIONS OF THERASENSE

         9.1   Supply of Products. TheraSense shall be responsible for the
               ------------------
manufacture of FreeStyle Products for sale to Nipro.

         9.2   Telephone Marketing and Technical Support. During TheraSense's
               -----------------------------------------
normal business hours, TheraSense shall provide, in English, a reasonable level
of telephone marketing and technical support to employees of Nipro who have been
trained by TheraSense to answer Nipro's questions related to FreeStyle Products.

         9.3   Intellectual Property Rights Maintenance.
               ----------------------------------------

               9.3.1     Patent and Trademark Prosecution. TheraSense will be
                         --------------------------------
responsible for maintaining all patents, Trademarks and trade names and/or
diligently prosecuting all patent applications

                                      -27-

*** Confidential treatment requested
<PAGE>

covering the FreeStyle Products in the Territory. TheraSense shall use its
reasonable commercial judgment in determining the level and extent of patent
protection to pursue in the Territory.

          9.3.2  Remedies for Injunction. If sale of the FreeStyle Products in
                 -----------------------
the Territory is enjoined due to any third party claim that the FreeStyle
Products or the trademark infringe the intellectual property rights of the third
party, then TheraSense may at its option and expense, (i) procure a license for
Nipro to continue selling FreeStyle Products, (ii) replace or modify the
FreeStyle Products to render them non-infringing; or (iii) if it is not
commercially reasonable to take the actions specified in items (i) and (ii),
terminate this Agreement with *** written notice to Nipro and repurchase from
Nipro the FreeStyle Products in Nipro's inventory as of the date of such
termination at Nipro's fully landed cost of such FreeStyle Products; provided,
however, that in such event, solely for purposes of Section 12.6.2, the date of
termination shall be considered to be the date the injunction is effective (as
such date may be extended by any stay or appeal of such injunction).

10.  CONFIDENTIALITY

     10.1 Except as expressly provided herein, the parties agree that for five
(5) years after the disclosure of any Confidential Information by one (1) of the
parties to the other hereto pursuant to this Agreement, the receiving party
shall keep completely confidential and shall not publish or otherwise disclose
and shall not use for any purpose except for the purposes contemplated by this
Agreement such Confidential Information, except that to the extent that it can
be established by the receiving party by competent proof that such Confidential
Information:

                 (a)  was already known to the receiving party, other than under
an obligation of confidentiality, at the time of disclosure;

                 (b)  was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving party;

                                      -28-

*** Confidential treatment requested
<PAGE>

                         (c)    became generally available to the public or
otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving party in breach of this Agreement;

                         (d)    was independently developed by the receiving
party as demonstrated by documented evidence prepared contemporaneously with
such independent development; or

                         (e)    was subsequently lawfully disclosed to the
receiving party by a person other than a party hereto.

          10.2   Permitted Use and Disclosures. Each party hereto may use or
                 -----------------------------
disclose information disclosed to it by the other party to the extent such use
or disclosure is reasonably necessary in complying with applicable governmental
regulations or otherwise submitting information to tax or other governmental
authorities, conducting clinical trials, or otherwise exercising its rights
hereunder, provided that if a party is required to make any such disclosure of
another party's confidential information, other than pursuant to a
confidentiality agreement, it will give reasonable advance notice to the latter
party of such disclosure and, except to the extent inappropriate in the case of
patent applications, will use its best efforts to secure confidential treatment
of such information prior to its disclosure (whether through protective orders
or otherwise).

          10.3   Public Disclosure. Except as otherwise required by law, neither
                 -----------------
party shall issue a press release or make any other public disclosure of the
terms of this Agreement without the prior approval of such press release or
public disclosure. Each party shall submit any such press release or public
disclosure to the other party, and the receiving party shall have ten (10)
business days to review and approve any such press release or public disclosure,
which approval shall not be unreasonably withheld. If the receiving party does
not respond in writing within such ten (10) business day period, the press
release or public disclosure shall be deemed approved.

                                      -29-
<PAGE>

     10.4  Confidential Terms. Except as expressly provided herein, each party
           ------------------
agrees not to disclose any terms of this Agreement to any third party without
the consent of the other party; provided, disclosures may be made as required by
securities or other applicable laws, or on a strict need to know basis to actual
or prospective investors, or to a party's accountants, attorneys and other
professional advisors; provided further, however, prior to making any disclosure
regarding securities or other applicable laws, the terms of this Agreement shall
be redacted by mutual agreement of the parties.

11.  INDEMNITY; INSURANCE; LIMITATION OF LIABILITY

     11.1  Indemnification of Nipro.
           ------------------------

           11.1.1  TheraSense shall indemnify, defend, and hold harmless Nipro
and its directors, officers and employees (each an "Nipro Indemnitee") from and
against any and all liabilities, damages, losses, costs or expenses (including
attorneys' and professional fees and other expenses of litigation and/or
arbitration) (a "Liability") resulting from a claim, suit or proceeding made or
brought by a third party against a Nipro Indemnitee arising from defects in
materials, workmanship, design or packaging of the FreeStyle Products, except
for matters for which Nipro is to indemnify TheraSense pursuant to Section
11.2.1.

           11.1.2  TheraSense shall defend, or at its option settle, any claims
brought against Nipro by third parties as a result of any infringement by the
FreeStyle Products of any U.S. or foreign patent, trade name, trademark, service
mark or copyright existing under the laws of the Territory, and shall reimburse
Nipro for any judgments, damages, cost or expenses payable by Nipro to a party
bringing such action together with reasonable attorneys' fees relating thereto.
If the FreeStyle Products, or any part thereof, are, or in the opinion of
TheraSense become, the subject of any claim for infringement of such third party
patent, trademarks, or copyrights, or if it is adjudicatively determined that
the FreeStyle Products, or any part thereof, infringe any such third party
patent trademark, or copyright, then

                                      -30-
<PAGE>

TheraSense may, at its option and expense, either (i) procure for Nipro the
right under such third party patent, trademark or copyright to sell or use, as
appropriate, the FreeStyle Products (or in the case of trademark infringement,
substitute a different trademark) or (ii) replace or modify the FreeStyle
Products or parts thereof in Nipro's possession, with other suitable and
reasonably equivalent technology or parts so that the FreeStyle Products become
non-infringing or (iii) if it is not commercially reasonable to take the actions
specified in items (i) or (ii) immediately preceding, terminate this Agreement
with ninety (90) days written notice.

               11.1.3 Notwithstanding the provisions of Section 11.1.2 above,
TheraSense assumes no liability for (i) infringements relating to any assembly,
circuit, combination, method or process made by anyone other than by or on
authority of TheraSense in which any of the FreeStyle Products may be used where
the FreeStyle Products when used alone would not result in such an infringement;
(ii) infringements involving the modification or servicing of the FreeStyle
Products, or any part thereof, done by anyone other than by or on authority of
TheraSense unless such modification or servicing was done by TheraSense; (iii)
any trademark infringements involving any marking or branding of the FreeStyle
Products not applied by TheraSense or at the request of TheraSense or involving
any marking or branding applied at the request of Nipro or any marking or
branding with Nipro or Kissei's trademarks; or (iv) modification of any
FreeStyle Products other than with TheraSense's written consent.

               11.1.4 The foregoing provisions of this Section 11.1 state the
entire liability and obligations of TheraSense, and the exclusive remedy of
Nipro and its Customers, with respect to any alleged product liability claim or
other matter covered by Section 11.1.1 related to the FreeStyle Products, or any
alleged infringement of any patents, copyrights, trademarks or other
intellectual property rights by the FreeStyle Products or any part thereof.

                                      -31-
<PAGE>

          11.2   Indemnification of TheraSense.
                 -----------------------------

                 11.2.1 Nipro shall indemnify, defend and hold harmless
TheraSense and its directors, officers, employees and agents and the successors
and assigns of any of the foregoing (each a "TheraSense Indemnitee") from any
and all claims, losses, costs, liabilities or expenses (including, without
limitation, attorneys' fees and other expenses of litigation) (a "Liability")
resulting from a claim, suit or proceeding made or brought by a third party
against a TheraSense Indemnitee arising out of (a) defects in the FreeStyle
Products sold by Nipro resulting from any action of Nipro, its Affiliates and
their Subdistributors, (b) FreeStyle Products claims, whether written or oral,
made by Nipro in its advertising, promotion, sale, or distribution of any of the
FreeStyle Products beyond those made by TheraSense, (c) the labeling, packaging,
storage or other handling, distribution or sale of the FreeStyle Products by
Nipro, its Affiliates or its Subdistributors except to the extent required by
TheraSense pursuant to this Agreement, or (d) any claim alleging noncompliance
by Nipro with Japan laws and regulations in the Territory which are equivalent
to the U.S. FDC&A.

                 11.2.2 Nipro shall defend, or at its option settle, any claims
brought against TheraSense by third parties as a result of any infringement by
the FreeStyle Products of any U.S. or foreign trademark, trade name, or service
mark existing under the laws of the Territory, and shall reimburse TheraSense
for any judgments, damages, cost or expenses payable by TheraSense to a party
bringing such action together with reasonable attorneys' fees relating thereto
as a result of marking or branding the FreeStyle Products with Nipro trademarks.
If the FreeStyle Products, or any part thereof, are, or in the opinion of Nipro
become, the subject of any claim for infringement of such third party
trademarks, trade names or service marks, or if it is adjudicatively determined
that the FreeStyle Products, or any part thereof, infringe any such third party
trademarks, trade names or service marks, Nipro may substitute a new Nipro
trademark, trade name or service mark to be used to sell or use, as appropriate,
the FreeStyle Products.

                                      -32-
<PAGE>

                 11.2.3 The foregoing provisions of this Section 11.2 state the
entire liability and obligations of Nipro, and the exclusive remedy of
TheraSense, with respect to any product liability or other matter covered by
Section 11.2.1 or any alleged infringement of any trademarks, trade names or
service marks by the FreeStyle Products or any part thereof.

          11.3   Indemnification Procedure. A party that intends to claim
                 -------------------------
indemnification (the "Indemnitee") under this Article 11 shall promptly notify
the other party (the "Indemnitor") in writing of any claim, complaint, suit,
proceeding or cause of action with respect to which the Indemnitee intends to
claim such indemnification (for purposes of this Section 11.3, each a "Claim"),
and the Indemnitor shall have sole control of the defense and/or settlement
thereof; provided that the Indemnitee shall have the right to participate, at
its own expense, with counsel of its own choosing in the defense and/or
settlement of such Claim. The indemnification obligations of the parties under
this Article 11 shall not apply to amounts paid in settlement of any Claim if
such settlement is effected without the consent of the Indemnitor, which consent
shall not be withheld or delayed unreasonably. The failure to deliver written
notice to the Indemnitor within a reasonable time after the commencement of any
such Claim shall relieve the Indemnitor of its liability to the Indemnitee under
this Article 11, only to the extent that the failure is prejudicial to its
ability to defend such action, but the omission so to deliver written notice to
the Indemnitor shall not relieve the Indemnitor of any liability to any
Indemnitee otherwise than under this Article 11. The Indemnitee under this
Article 11, and its employees, at the Indemnitor's request and expense, shall
provide full information and reasonable assistance to Indemnitor and its legal
representatives with respect to such Claims covered by this indemnification. It
is understood that only Nipro may claim indemnity under this Article 11 (on its
own behalf or on behalf of an Nipro Indemnitee), and other Nipro Indemnitees may
not directly claim indemnity hereunder. Likewise, it is understood that only
TheraSense may claim indemnity under this Article 11 (on its own behalf or on

                                      -33-
<PAGE>

behalf of a TheraSense Indemnitee), and other TheraSense Indemnitees may not
directly claim indemnity hereunder.

         11.4   Insurance. During the term of this Agreement, each party shall
                ---------
maintain liability insurance policies, including without limitation, product
liability insurance coverage, in commercially adequate amounts. TheraSense's
policy shall name Nipro as an additional insured and contain an endorsement to
provide Nipro with at least thirty (30) days prior written notice of any
cancellation or nonrenewal of such policy. Each party shall furnish to the other
party copies of such policies.

         11.5   LIMITED LIABILITY.
                -----------------

                11.5.1  EXCEPTING THE PROVISIONS OF SECTION 12.6.2, THERASENSE'S
LIABILITY ARISING OUT OF THIS AGREEMENT, THE TERMINATION THEREOF, AND/OR SALE OF
THE FREESTYLE PRODUCTS SHALL BE LIMITED TO THE AMOUNT OF TEN MILLION DOLLARS
(USD $10,000,000).

                11.5.2  IN NO EVENT SHALL THERASENSE OR NIPRO BE LIABLE TO THE
OTHER OR ANY OTHER ENTITY FOR LOST PROFITS, OR ANY OTHER SPECIAL, CONSEQUENTIAL,
OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY ARISING OUT
OF THIS AGREEMENT, OR ANY TERMINATION THEREOF, WHETHER BASED IN CONTRACT, TORT
(INCLUDING NEGLIGENCE), OR OTHERWISE. THESE LIMITATIONS SHALL APPLY WHETHER OR
NOT THERASENSE OR NIPRO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN OR IN THE WARRANTY FOUND IN THE FREESTYLE PRODUCTS.

                                      -34-

<PAGE>

12.  TERM AND TERMINATION

     12.1   Initial Term.
            ------------

            12.1.1 Initial Term. The initial term of this Agreement shall
                   ------------
commence on the Effective Date and shall continue in force until five (5) years
from the Effective Date, unless terminated earlier under the provisions of this
Article 12 (the "Initial Term").

            12.1.2 Extended Term. Beginning in fourth (4th) year of this
                   -------------
Agreement, and each year thereafter, the term of this Agreement may be extended
by up to an additional three (3) years (each an "Extended Term") as follows:

                   (a)   At any time during the last three (3) months of the
fourth (4th) year, either party may notify the other party that it would like to
extend the term by an additional rolling three (3) years (i.e. to add years 6,
7, and 8 to the initial five (5) years). The parties shall then meet and agree
to the Annual Minimum Purchase Obligation of Strips that shall apply for each
additional year. If the parties so agree, this Agreement shall be so extended.

                   (b)   Provided that the parties agreed to extend this
Agreement at the end of the fourth (4th) year and this Agreement is then still
in effect, during the last three (3) months of any subsequent year, the parties
may meet to extend the term by an additional rolling three (3) years (e.g., in
the last three (3) months of the fifth (5th) year, the parties may agree to add
years 7, 8 and 9, and so forth). During any Extended Term, all the terms of this
Agreement shall apply, including without limitation Section 8.5.

                   (c)   Notwithstanding anything to the contrary, neither party
is obligated to agree on a new Annual Minimum Purchase Obligation of Strips;
provided, however, that if the parties are unable to agree on such new Annual
Minimum Purchase Obligation for the extension years prior to

                                      -35-
<PAGE>

the end of the three (3) month period, TheraSense shall be free to enter into a
distribution agreement with any third party following termination of this
agreement but only if the new agreement contains annual minimum purchase
obligations greater than those offered to and rejected by Nipro prior to the
end of the three (3) month period.

          12.2   Termination for Cause. If either party defaults in the
                 ---------------------
performance of any provision of this Agreement, then the non-defaulting party
may give written notice to the defaulting party that if the default is not cured
within ninety (90) days the Agreement will be terminated. If the non-defaulting
party gives such notice and the default is not cured during the ninety (90) day
period, then the Agreement shall automatically terminate at the end of that
period. In addition, this Agreement shall automatically terminate if Nipro fails
to pay TheraSense in accordance with Sections 3.1 or 3.2 and such failure shall
have continued for thirty (30) days after written notice thereof was provided to
Nipro by TheraSense.

          12.3   Termination for Insolvency. This Agreement may be terminated by
                 --------------------------
either party effective immediately upon written notice (i) upon the institution
by or against the other party of insolvency, receivership or bankruptcy
proceedings or any other proceedings for the settlement of the other party's
debts under United States, California or Japan law, (ii) upon the other party's
making an assignment for the benefit of creditors, or (iii) upon the other
party's dissolution or ceasing to do business.

          12.4   Termination Relating to ***.
                 ---------------------------

                 12.4.1 ***. TheraSense may, at its sole discretion, terminate
                        ---
this Agreement *** if Nipro ***, without TheraSense's prior written
consent.

                                      -36-

*** Confidential treatment requested
<PAGE>

                 12.4.2  ***. Should Nipro decide to ***, it shall so notify
                         ---
TheraSense in writing ***. Nipro's obligation to provide such notice, shall
survive termination of this Agreement by TheraSense pursuant to Section 12.2 or
Section 12.4.1.

          12.5   Termination Relating to Sales Outside Territory.
                 -----------------------------------------------

                 12.5.1 In addition to any other rights or remedies available to
TheraSense, TheraSense shall have the right to terminate this Agreement upon
thirty (30) days prior written notice to Nipro if Nipro is selling the FreeStyle
Products in commercial quantities, (i) for delivery outside the Territory or
(ii) with knowledge that the FreeStyle Products are being purchased for use or
resale outside the territory, unless Nipro cures such breach within such thirty
(30) day period.

                 12.5.2 In the event either TheraSense or Nipro become aware
that any Nipro Affiliate or Subdistributor (including without limitation
distributors, wholesalers, and retailers) has directly or indirectly resold or
reshipped any of the FreeStyle Products outside the Territory in commercial
quantities, it shall notify the other party in writing. In the event that either
of the parties determine that such Nipro Affiliate or Subdistributor (including
without limitation distributors, wholesalers, and retailers) knew or should have
known that such FreeStyle Products were ultimately being resold or reshipped
outside the Territory, it shall notify the other party and Nipro shall take all
necessary action to stop such activities, including without limitation
terminating the right of such third party to distribute and sell FreeStyle
Products, in accordance with its agreement with the Subdistributor.

                                      -37-

*** Confidential treatment requested
<PAGE>

          12.6   Effect of Termination.
                 ---------------------

                 12.6.1 Accrued Obligations. Expiration or termination of this
                        -------------------
Agreement for any reason shall not release any party hereto from any liability
which, at the time of such termination, has already accrued to the other party
or which is attributable to a period prior to such termination nor preclude
either party from pursuing any rights and remedies it may have hereunder or at
law or in equity with respect to any breach of this Agreement. It is understood
and agreed that monetary damages may not be a sufficient remedy for any breach
of this Agreement and that the non-breaching party may be entitled to injunctive
relief as a remedy for any such breach. Such remedy shall not be deemed to be
the exclusive remedy for any such breach of this Agreement, but shall be in
addition to all other remedies available at law or in equity.

                 12.6.2 Signature Payment. If during the Initial Term,
                        -----------------
TheraSense terminates this Agreement pursuant to Section 9.3.2 or 11.1.2, or
Nipro terminates this Agreement pursuant to Section 12.2 due to TheraSense's
material breach, TheraSense shall repay to Nipro a portion of the Signature
Payment paid by Nipro to TheraSense pursuant to Section 3.1 as follows:

                        (a) immediately prior to the effective date of
Termination the parties shall determine the number of full years remaining in
the Initial Term; and

                        (b) for each full year remaining in the Initial Term,
TheraSense shall repay to Nipro Five Hundred Thousand Dollars (USD $500,000).

                        (c) Except as provided for in this Section 12.6.2,
TheraSense shall have no obligation to repay any of the Signature Payment to
Nipro.

                 12.6.3 Approvals. Upon any termination or expiration of this
                        ---------
Agreement, Nipro shall (and shall ensure that its Affiliates and Subdistributors
shall): (i) assign to TheraSense all right, title and

                                      -38-

<PAGE>

interest to the Approvals (as defined in Section 8.1), and (ii) execute those
documents, as reasonably requested by TheraSense, necessary to document and/or
perfect the assignment of such registrations, approvals and government
authorizations. TheraSense shall have the exclusive right to use all such
registrations, licenses or permits upon expiration or termination of this
Agreement for any reason. In the event that the Approvals cannot be transferred
to TheraSense or its designated agent in time for the uninterrupted continuation
of sales of FreeStyle Product in the Territory, Nipro shall cooperate with
TheraSense to assure continued supply until such time as Approvals are
transferred so as to allow continued FreeStyle Product supply.

                 12.6.4 Inventory. Within twenty (20) days after the effective
                        ---------
date of termination of this Agreement, Nipro shall use its reasonable efforts to
provide TheraSense with a complete inventory of FreeStyle Products in Nipro's
possession, in transit to Nipro from TheraSense or otherwise in Nipro's control.
Upon any expiration or other termination of this Agreement, TheraSense may
inspect Nipro's FreeStyle Products inventory and audit Nipro's records.

                 12.6.5 Products. Upon termination of this Agreement, TheraSense
                        --------
shall have the option, at its sole discretion, to repurchase or have purchased
by its agent, all or part of Nipro or sub-distributor inventories of saleable
FreeStyle Product. In such case, TheraSense or its agent shall pay Nipro its
original landed cost for the Product so repurchased, or in the case of Nipro
packaged FreeStyle Product, the inventory value of such repurchased goods
according to Nipro's inventory accounting.

                 12.6.6 Return of Materials. All of TheraSense's trademarks,
                        -------------------
marks, trade names, patents, and copyrights, and all designs, drawings, formulas
or other data, photographs, samples, literature, and sales and promotional aids
of every kind related to the FreeStyle Products provided by TheraSense, shall
remain the property of TheraSense. Within thirty (30) days after the effective
date of termination of this Agreement, Nipro shall destroy all tangible items
bearing, containing, or contained in,

                                      -39-
<PAGE>

any of the foregoing, in its possession or control and provide written
certification of such destruction, or prepare such tangible items for shipment
to TheraSense, as TheraSense may direct, at TheraSense's expense. Nipro shall
not make or retain any copies of any confidential items or information which may
have been entrusted to it. Effective upon the termination of this Agreement,
Nipro shall cease to use all trademarks and trade names of TheraSense. During
the term of this Agreement and after any termination or expiration of this
Agreement, TheraSense shall have the right to continue to use and disclose for
any purpose any and all clinical trial results and other data relating to the
FreeStyle Products.

          12.6.7 Transition. Upon termination of this Agreement, Nipro shall use
                 ----------
commercially reasonable efforts to cooperate with TheraSense to effect a smooth
and orderly transition in the sale of FreeStyle Products in the Territory. After
the effective termination date, Nipro shall refer all FreeStyle Products
inquiries to TheraSense and shall provide commercially reasonable cooperation to
any newly-appointed distributors.

          12.6.8 No Renewal, Extension or Waiver. Acceptance of any order from,
                 -------------------------------
or sale of, any FreeStyle Products to Nipro after the date of termination of
this Agreement shall not be construed as a renewal or extension hereof, or as a
waiver of termination by TheraSense.

     12.7 Survival. The provisions of Sections 2.4, 2.6, 3.2.4, 3.3, 4.4.4, 5.6,
          --------
6.1, 7.2.2, 8.1.3, 8.3, 8.6, 8.9, 8.10, 8.12 (but only with respect to
Improvements reduced to practice prior to the effective date of termination),
12.4.2, 12.6, and 12.7 and Articles 10, 11 (but only to the extent such
indemnity claim arises from act or omissions that occurred prior to the
effective date of termination), 13 and 14 shall survive the expiration or
termination of this Agreement for any reason. All other rights and obligations
of the parties shall cease upon termination of this Agreement.

                                      -40-
<PAGE>

13.  DISPUTE RESOLUTION

     13.1 Chief Executive Officers. If a dispute, controversy or claim between
          ------------------------
the parties arising out of or relating to the validity, construction,
enforceability or performance of this Agreement, including disputes relating to
alleged breach or to termination of this Agreement (each, a "Dispute"), either
Nipro or TheraSense may, by written notice to the other, have such dispute
referred to the General Manager of Nipro, or his designee, and to the Vice
President of International Business Development of TheraSense, or his designee
for resolution. If, within thirty (30) days of such written notification of a
Dispute, no resolution is agreed between the parties, the dispute will be
presented to the Chief Executive Officer of Nipro, and the President of
TheraSense for resolution. If, within sixty (60) days of written notification of
a Dispute, no resolution is agreed, then either party may notify the other party
that it invokes resolution of the dispute by binding arbitration in the manner
described in Section 13.2 ("ADR").

     13.2 Arbitration.
          -----------

          13.2.1 Any Dispute that cannot be settled amicably by agreement of the
parties pursuant to Section 13.1 above shall be finally settled by binding
arbitration in the manner described in this Section 13.2. The ADR shall be
conducted pursuant to then obtaining Rules of Arbitration of the London Court of
International Arbitration, by which each party hereto agrees to be bound.
Notwithstanding those rules, the ADR shall be held in London, England by a
single arbitrator, provided that at the request of any party, the arbitration
shall be conducted by a panel of three (3) arbitrators, with one (1) arbitrator
chosen by each of TheraSense and Nipro and the third appointed by the other two
(2) arbitrators. The parties shall use their best efforts to select the
arbitrator(s) within ninety (90) days of the initiation of ADR. It is understood
and agreed that the filing by a party of an action that is subject to this
Section 13.2, whether in court or in arbitration, shall constitute an
"initiation" of ADR. Each party agrees that any such action filed in court shall
be stayed pending the outcome of the related ADR. The

                                      -41-
<PAGE>

arbitrator(s) selected in accordance with this Section 13.2 are referred to
herein as the "Panel" and shall be comprised of independent experts with
experience in the field of the dispute.

          13.2.2 All ADR proceedings, including without limitation the filing of
any documents, papers, and/or motions relating thereto, shall be made in the
English language. In the event of any dispute concerning the construction or
meaning of such documents, papers and/or motions, reference shall be made only
to such documents, papers and/or motions as written in English and not to any
translation into any other language.

          13.2.3 The decision and/or award rendered by the Panel shall be
written (specifically stating the Panel's findings of facts as well as the
reasons upon which the Panel's decision is based), final and nonappealable
(except for an alleged act of corruption or fraud on the part of the Panel) and
may be entered in any court of competent jurisdiction. The parties agree that,
any provision of applicable law notwithstanding, they will not request, and the
Panel shall have no authority to award, punitive or exemplary damages against
any party. The Panel shall have the authority to grant injunctive relief and
order specific performance. The Panel shall determine what discovery will be
permitted, consistent with the goal of limiting the cost and time which the
parties must expend for discovery; provided the Panel shall permit such
discovery as they deem necessary to permit an equitable resolution of the
dispute. Evidence need not be obtained in the presence of the Panel. At the
arbitration hearing, each party may make written and oral presentations to the
Panel, present testimony and written evidence, and examine witnesses. The costs
of any arbitration, including administrative fees and fees of the Panel, shall
be shared equally by the parties. Each party shall bear the cost of its own
attorneys' fees and expert fees. The parties and the Panel shall use their best
efforts to complete any such arbitration within one (1) year after the
appointment of the Panel, unless a party can demonstrate to the Panel that the
complexity of the issues or other reasons warrant the extension of the time
table. In such case, the Panel may extend such time table as reasonably
required. The Panel shall, in rendering its decision, apply the substantive law
of

                                      -42-
<PAGE>

the State of Delaware, without regard to its conflict of laws provisions, except
that the interpretation of and enforcement of this Section 13.2 shall be
governed by the Rules of Arbitration of the International Chamber of Commerce.
No party shall initiate arbitration hereunder unless it has attempted to resolve
the dispute in accordance with Section 13.1.

          13.2.4 Injunctive Relief. This Section 13.2 shall not be construed to
                 -----------------
prohibit either party from seeking preliminary or permanent injunctive relief,
restraining order or degree of specific performance in any court of competent
jurisdiction to the extent not prohibited by this Agreement. For avoidance of
doubt, any such equitable remedies provided under this Section 13.2 shall be
cumulative and not exclusive and are in addition to any other remedies, which
either party may have under this Agreement or applicable law.

14.  MISCELLANEOUS

     14.1 Governing Law. This Agreement, and any proceeding subject to Article
          -------------
13, shall be governed by and construed in accordance with the laws of the State
of Delaware, without reference to principles of conflicts of laws.

     14.2 Independent Contractors. The relationship of the parties hereto is
          -----------------------
that of independent contractors. The parties hereto are not deemed to be agents,
partners or joint venturers of the other for any purpose as a result of this
Agreement or the transactions contemplated thereby.

     14.3 U.S. Export Control. Nipro certifies that unless prior written
          -------------------
authorization is obtained from the U.S. Bureau of Export Administration or the
U.S. Export Administration Regulations explicitly permit the re-export without
such authorization, it will not export, re-export, or transship, directly or
indirectly, the FreeStyle Products, documentation, technical assistance, or any
media in which any of the foregoing is contained, or other technology provided
hereunder or the direct product thereof, to any

                                      -43-
<PAGE>

country as to which the U.S. Government has placed an embargo against the
shipment of products, software or technology which embargo is in effect during
the term of this Agreement.

     14.4 Assignment. The parties agree that their rights and obligations under
          ----------
this Agreement shall not be delegated, transferred or assigned to a third party
without prior written consent of the other party hereto; provided either party
may assign this Agreement, without the other party's consent (a) to its
Affiliates, and (b) to an entity that acquires all or substantially all of the
business or assets of the assigning party to which this Agreement pertains,
whether by merger, reorganization, acquisition, sale or otherwise. This
Agreement shall be binding upon and inure to the benefit of the parties and
their successors and assigns.

                                      -44-
<PAGE>

     14.5 Notices. All notices required or permitted hereunder shall be given in
          -------
writing addressed to the respective parties as set forth below and shall either
be (i) personally delivered, (ii) sent by internationally-recognized private
express courier; or (iii) sent by facsimile, with a confirmation copy sent
within one (1) business day thereafter by internationally-recognized private
express courier. Notices shall be deemed to have been given on the date of
receipt if delivered personally, or two (2) days after deposit with an express
courier, or upon transmission if sent by facsimile with a confirmation copy sent
as provided herein. Either party may change its address for purposes hereof by
written notice to the other in accordance with the provisions of this Section.
The addresses for the parties are as follows:

     If to Nipro:            Nipro Corporation
                             3-9-3, Honjo-Nishi, Kita-ku
                             Osaka, Japan
                             Attention: CEO

     If to TheraSense:       TheraSense, Inc.
                             1360 South Loop Road
                             Alameda, CA 94502
                             USA
                             Attention: CEO

     14.6 Force Majeure. Neither party shall lose any rights hereunder or be
          -------------
liable to the other party for damages or losses (except for payment obligations)
on account of failure of performance by the defaulting party if the failure is
occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, or any other reason where
failure to perform is beyond the reasonable control and not caused by the
negligence, intentional conduct or misconduct of the nonperforming party and
such party has exerted all reasonable efforts to avoid or remedy such force
majeure; provided, however, that in no event shall a party be required to settle
any labor dispute or disturbance.

                                      -45-
<PAGE>

     14.7  Advice of Counsel. TheraSense and Nipro have each consulted counsel
           -----------------
of their choice regarding this Agreement, and each acknowledges and agrees that
this Agreement shall not be deemed to have been drafted by one party or another
and will be construed accordingly.

     14.8  Compliance with Laws. Each party shall furnish to the other party any
           --------------------
information requested or required by that party during the term of this
Agreement or any extensions hereof to enable that party to comply with the
requirements of any U.S. or foreign, state and/or government agency.

     14.9  Further Assurances. At any time or from time to time on and after the
           ------------------
date of this Agreement, Nipro shall at the request of TheraSense (i) deliver to
TheraSense such records, data or other documents consistent with the provisions
of this Agreement, (ii) execute, and deliver or cause to be delivered, all such
consents, documents or further instruments of transfer or license, and (iii)
take or cause to be taken all such actions, as TheraSense may reasonably deem
necessary or desirable in order for TheraSense to obtain the full benefits of
this Agreement and the transactions contemplated hereby.

     14.10 Severability; Waiver. In the event that any provisions of this
           --------------------
Agreement are determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and
effect without said provision. The parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the parties in entering this
Agreement. The failure of a party to enforce any provision of the Agreement
shall not be construed to be a waiver of the right of such party to thereafter
enforce that provision or any other provision or right.

     14.11 Entire Agreement; Modification. This Agreement sets forth the entire
           ----------------
agreement and understanding of the parties with respect to the subject matter
hereof, and supersedes all prior discussions, agreements and writings in
relating thereto. This Agreement may not be altered, amended or modified in any
way except by a writing signed by both parties.

                                      -46-
<PAGE>

     14.12 Counterparts. This Agreement may be executed in two counterparts,
           ------------
each of which shall be deemed an original and which together shall constitute
one instrument.

     IN WITNESS WHEREOF, Nipro and TheraSense have executed this Agreement by
their respective duly authorized representatives.

NIPRO CORPORATION                           THERASENSE, INC.

    /s/ Signature                                /s/ Signature
By:_______________________________          By:______________________________

Print Name:_______________________          Print Name:______________________

Title:____________________________          Title:___________________________

                                      -47-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]